Cargando…

S180: RESULTS OF A PHASE 3 TRIAL OF AN ORAL CXCR4 ANTAGONIST, MAVORIXAFOR, FOR TREATMENT OF PATIENTS WITH WHIM SYNDROME

Detalles Bibliográficos
Autores principales:	Badolato, Raffaele, Donadieu, Jean
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Oral Sessions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428373/ http://dx.doi.org/10.1097/01.HS9.0000967632.68470.0a

Ejemplares similares

PB1938: 4WHIM: EVALUATING MAVORIXAFOR, AN ORAL CXCR4 ANTAGONIST, IN PATIENTS WITH WHIM SYNDROME VIA A GLOBAL PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL WITH OPEN-LABEL EXTENSION
por: Dale, D. C., et al.
Publicado: (2022)

Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma
por: Andtbacka, Robert H.I., et al.
Publicado: (2022)

Genotype–phenotype correlations in WHIM syndrome: a systematic characterization of CXCR4(WHIM) variants
por: Zmajkovicova, Katarina, et al.
Publicado: (2022)

WHIM Syndrome-linked CXCR4 mutations drive osteoporosis
por: Anginot, Adrienne, et al.
Publicado: (2023)

Aberrant CXCR4 Signaling at Crossroad of WHIM Syndrome and Waldenstrom’s Macroglobulinemia
por: Milanesi, Samantha, et al.
Publicado: (2020)

WHIM Syndrome With a Novel CXCR4 Variant in a Korean Child
por: Shin, Dong Woo, et al.
Publicado: (2017)

AMD3100 is a potent antagonist at CXCR4(R334X), a hyperfunctional mutant chemokine receptor and cause of WHIM syndrome
por: McDermott, David H, et al.
Publicado: (2011)

S147: EFFICACY AND SAFETY RESULTS OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROME
por: Frustaci, Anna Maria, et al.
Publicado: (2023)

CXCL12/CXCR4-Axis Dysfunctions: Markers of the Rare Immunodeficiency Disorder WHIM Syndrome
por: Bachelerie, Françoise
Publicado: (2010)

Adaptive Immunodeficiency in WHIM Syndrome
por: Majumdar, Shamik, et al.
Publicado: (2018)

S172: PHASE 1/2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH VENETOCLAX IN TREATMENT-NAÏVE HIGHER-RISK MYELODYSPLASTIC SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA
por: Bataller, Alex, et al.
Publicado: (2023)

Whims of Hysteria
Publicado: (1885)

Altered CXCR4 dynamics at the cell membrane impairs directed cell migration in WHIM syndrome patients
por: García-Cuesta, Eva M., et al.
Publicado: (2022)

S133: AN ENTIRELY ORAL REGIMEN OF ORAL-ATO, ATRA AND ASCORBIC ACID IN RISK-ADAPTED TREATMENT OF NEWLY-DIAGNOSED APL RESULTED IN EXCELLENT CLINICAL/MOLECULAR RESPONSES WITH DURABLE REMISSION
por: Gill, Harry, et al.
Publicado: (2023)

Characterization of a new WHIM syndrome mutant reveals mechanistic differences in regulation of the chemokine receptor CXCR4
por: Luo, Jiansong, et al.
Publicado: (2021)

P793: SCREENING OF NATURALLY OCCURRING CXCR4 VARIANTS FOR IDENTIFICATION OF NOVEL PATHOGENIC MUTATIONS FOR WHIM SYNDROME
por: Pawar, S., et al.
Publicado: (2022)

CCR5 and CXCR4 antagonist and agonist binding sites
por: Teintze, Martin, et al.
Publicado: (2006)

S181: THE PHASE III, RANDOMIZED COMMODORE 2 TRIAL: RESULTS FROM A MULTICENTER STUDY OF CROVALIMAB VS ECULIZUMAB IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) PATIENTS NAIVE TO COMPLEMENT INHIBITORS
por: Röth, Alexander, et al.
Publicado: (2023)

S213: BMS-986158, A POTENT BET INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH RUXOLITINIB OR FEDRATINIB IN INTERMEDIATE- OR HIGH-RISK MYELOFIBROSIS (MF): RESULTS FROM A PHASE 1/2 STUDY
por: Ayala, Rosa, et al.
Publicado: (2023)

S200: IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT-NAÏVE EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF THE PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED CLL12 TRIAL
por: Langerbeins, Petra, et al.
Publicado: (2023)

New Insights on the Emerging Genomic Landscape of CXCR4 in Cancer: A Lesson from WHIM
por: Scala, Stefania, et al.
Publicado: (2020)

S276: POVETACICEPT (ALPN-303), A POTENT DUAL BAFF/APRIL ANTAGONIST, FOR THE TREATMENT OF AUTOIMMUNE CYTOPENIAS AND OTHER ANTIBODY-RELATED DISEASES
por: Dillon, Stacey, et al.
Publicado: (2023)

S202: CARTITUDE-1 FINAL RESULTS: PHASE 1B/2 STUDY OF CILTACABTAGENE AUTOLEUCEL IN HEAVILY PRETREATED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Munshi, Nikhil, et al.
Publicado: (2023)

S299: ORELABRUTINIB, AN IRREVERSIBLE INHIBITOR OF BRUTON’S TYROSINE KINASE, FOR TREATMENT OF PRIMARY IMMUNE THROMBOCYTOPENIA: RESULTS OF A RANDOMIZED, OPEN-LABEL PHASE II STUDY
por: Shi, Yan, et al.
Publicado: (2023)

S132: UPDATED RESULTS OF VEN-A-QUI STUDY: A PHASE 1-2 TRIAL TO ASSESS THE SAFETY AND EFFICACY OF TRIPLETS FOR NEWLY DIAGNOSED UNFIT AML PATIENTS: AZACITIDINE OR LOW-DOSE CYTARABINE WITH VENETOCLAX AND QUIZARTINIB
por: Miguel Bergua Burgues, Juan, et al.
Publicado: (2023)

Case Report: A Novel CXCR4 Mutation in a Chinese Child With Kawasaki Disease Causing WHIM Syndrome
por: Ma, Xiaopeng, et al.
Publicado: (2022)

S264: EDIT-301 SHOWS PROMISING PRELIMINARY SAFETY AND EFFICACY RESULTS IN THE PHASE I/II CLINICAL TRIAL (RUBY) OF PATIENTS WITH SEVERE SICKLE CELL DISEASE USING HIGHLY SPECIFIC AND EFFICIENT ASCAS12A ENZYME
por: Hanna, Rabi, et al.
Publicado: (2023)

S207: NAVTEMADLIN, AN ORAL MDM2 INHIBITOR, ELIMINATES MYELOPROLIFERATIVE NEOPLASM-BLAST PHASE (MPN-BP) INITIATING CELLS AND PROLONGS LEUKEMIA-FREE SURVIVAL (LFS) IN AN MPN-BP PDX MODEL
por: Wang, Xiaoli, et al.
Publicado: (2023)

Reduced G protein signaling despite impaired internalization and β-arrestin recruitment in patients carrying a CXCR4(Leu317fsX3) mutation causing WHIM syndrome
por: Kumar, Rajesh, et al.
Publicado: (2023)

S156: FRONTLINE ASCIMINIB COMBINATION IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS. THE FASCINATION TRIAL.
por: Ernst, Thomas, et al.
Publicado: (2023)

S246: JAK/ROCK INHIBITOR TQ05105 FOR GLUCOCORTICOID-REFRACTORY OR -DEPENDENT CHRONIC GRAFT-VERSUS-HOST DISEASE: UPDATED RESULTS OF A PHASE 1B/2 STUDY
por: Zhao, Yanmin, et al.
Publicado: (2023)

S191: PIVOTAL PHASE 2 MONUMENTAL-1 RESULTS OF TALQUETAMAB (TAL), A GPRC5DXCD3 BISPECIFIC ANTIBODY (BSAB), FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
por: Touzeau, Cyrille, et al.
Publicado: (2023)

S146: GENOMIC EVOLUTION AND RESISTANCE TO PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR (CBTKI) PRE-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS: RESULTS FROM THE PHASE I/II BRUIN STUDY
por: Brown, Jennifer R., et al.
Publicado: (2023)

S132: TOLERABILITY AND EFFICACY OF THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY MAGROLIMAB COMBINED WITH AZACITIDINE IN FRONTLINE PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA: PHASE 1B RESULTS
por: Daver, N. G., et al.
Publicado: (2022)

S204: SAFETY AND TOLERABILITY OF CAEL-101, AN ANTI-AMYLOID MONOCLONAL ANTIBODY, COMBINED WITH ANTI-PLASMA CELL DYSCRASIA THERAPY IN PATIENTS WITH LIGHT-CHAIN AMYLOIDOSIS: 18-MONTH RESULTS OF A PHASE 2 STUDY
por: Valent, Jason, et al.
Publicado: (2023)

S224: HIGH COMPLETE RESPONSE RATE WITH TNB-486, A NOVEL CD19XCD3 T-CELL ENGAGER, IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: INTERIM RESULTS FROM AN ONGOING PHASE 1 STUDY
por: Jacobs, Ryan, et al.
Publicado: (2023)

S165: CONTINUOUS TRANFUSION INDEPENDENCE WITH IMETELSTAT IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS IN IMERGE PHASE 3
por: Platzbecker, Uwe, et al.
Publicado: (2023)

Description and outcome of a cohort of 8 patients with WHIM syndrome from the French Severe Chronic Neutropenia Registry
por: Beaussant Cohen, Sarah, et al.
Publicado: (2012)

S164: DISEASE MODIFYING ACTIVITY OF IMETELSTAT IN PATIENTS WITH HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS IN IMERGE PHASE 3
por: Santini, Valeria, et al.
Publicado: (2023)

A chemotaxis model to explain WHIM neutrophil accumulation in the bone marrow of WHIM mouse model
por: Yip, Ai Kia, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_nvoldocg3th8b1emq407dt4l72